Small molecule inhibitors targeting ref-1/ape1 for pancreatic cancer
Innovative Ref-1 inhibitors aim to enhance pancreatic cancer treatment by disrupting cancer cell metabolism and growth. This technology targets Ref-1, a key regulator in cancer cell signaling, potentially improving patient outcomes through combination therapies.
Overview
This solution involves the development of small molecule inhibitors that specifically target Redox factor-1 (Ref-1), a critical regulator of transcription factors involved in pancreatic cancer progression and drug resistance. By inhibiting Ref-1, these compounds disrupt cancer cell metabolism and growth, offering a novel approach to treating pancreatic ductal adenocarcinoma (PDAC). Given PDAC's resistance to conventional therapies, these inhibitors provide a promising strategy to induce metabolic lethality in cancer cells, potentially improving patient outcomes, especially when used in combination therapies.
Technical specifications
Key features:
- Targeted Inhibition: Focus on the redox function of Ref-1 to interfere with cancer cell signaling pathways.
- Lead Optimization: Compounds are at the lead optimization stage, supported by a detailed structural-activity relationship (SAR) program.
- Combination Potential: Designed for use in combination with other treatments to overcome resistance mechanisms.
- Clinical Validation: First-generation Ref-1 inhibitors have completed phase I trials, with second-generation compounds in development.
Applications:
- Treatment of pancreatic ductal adenocarcinoma (PDAC)
- Potential to enhance efficacy of existing therapies through combination use
Technology readiness level
This technology is currently at Technology Readiness Level 6, indicating it is in the validation phase with prototypes being tested in relevant environments. Ongoing evaluation includes enhancing the efficacy and pharmacokinetic properties of the inhibitors to prepare for further clinical trials.
About Indiana University
Indiana University is a comprehensive public research university system serving the state through flagship and urban campuses and a broad mix of liberal arts and professional programs. Industry engagement is anchored by integration with a major hospital system and a large medical school, enabling clinical access and translational pathways in Indianapolis. Co-located labs, corporate-sponsored capstones, and internship pipelines connect companies with faculty and student talent across a statewide campus network. Research is supported by competitive funding from agencies such as the NIH, NSF, and the U.S. Department of Defense, along with state and industry partners. A dedicated technology transfer office and venture arm provide IP management, licensing, and startup support.
delivered to your inbox.